These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 9931388)
1. Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition. Bramhall SR J Hepatobiliary Pancreat Surg; 1998; 5(4):392-401. PubMed ID: 9931388 [TBL] [Abstract][Full Text] [Related]
2. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Bramhall SR Int J Pancreatol; 1997 Feb; 21(1):1-12. PubMed ID: 9127168 [TBL] [Abstract][Full Text] [Related]
4. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Jones L; Ghaneh P; Humphreys M; Neoptolemos JP Ann N Y Acad Sci; 1999 Jun; 880():288-307. PubMed ID: 10415874 [TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Rasmussen HS; McCann PP Pharmacol Ther; 1997; 75(1):69-75. PubMed ID: 9364582 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Bloomston M; Zervos EE; Rosemurgy AS Ann Surg Oncol; 2002 Aug; 9(7):668-74. PubMed ID: 12167581 [TBL] [Abstract][Full Text] [Related]
7. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Rosemurgy A; Harris J; Langleben A; Casper E; Goode S; Rasmussen H Am J Clin Oncol; 1999 Jun; 22(3):247-52. PubMed ID: 10362330 [TBL] [Abstract][Full Text] [Related]
9. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. Bramhall SR; Neoptolemos JP; Stamp GW; Lemoine NR J Pathol; 1997 Jul; 182(3):347-55. PubMed ID: 9349239 [TBL] [Abstract][Full Text] [Related]
10. Complex roles of tissue inhibitors of metalloproteinases in cancer. Jiang Y; Goldberg ID; Shi YE Oncogene; 2002 Mar; 21(14):2245-52. PubMed ID: 11948407 [TBL] [Abstract][Full Text] [Related]
11. Role of matrix metalloproteinases and their inhibitors in pancreatic cancer. Evans JD; Ghaneh P; Kawesha A; Neoptolemos JP Digestion; 1997; 58(6):520-8. PubMed ID: 9438596 [TBL] [Abstract][Full Text] [Related]
12. Marimastat: BB 2516, TA 2516. Drugs R D; 2003; 4(3):198-203. PubMed ID: 12757409 [TBL] [Abstract][Full Text] [Related]
13. A phase II trial of marimastat in advanced pancreatic cancer. Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327 [TBL] [Abstract][Full Text] [Related]
14. Marimastat (BB2516): current status of development. Steward WP Cancer Chemother Pharmacol; 1999; 43 Suppl():S56-60. PubMed ID: 10357560 [TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibitors: applications in oncology. Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405 [TBL] [Abstract][Full Text] [Related]
16. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Zucker S; Cao J; Chen WT Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650 [TBL] [Abstract][Full Text] [Related]